Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Increases Expected Billings for MaterniT21 Plus to 40,000 in 2012

NEW YORK (GenomeWeb News) – Sequenom today raised its estimates for the number of billed MateriT21 Plus tests for 2012 to 40,000 as adoption of the test accelerated during the first quarter.

The San Diego-based firm had previously forecast 25,000 billings for the non-invasive fetal aneuploidy test for the year.

In the first quarter, Sequenom saw more than 12,700 total tests, including more than 4,900 MaterniT21 Plus tests, accessioned in Q1, it said. Based on the volume processed during the last week of the quarter, the annualized run rate for MaterniT21 Plus would be more than 30,000 tests.

Sequenom Chairman and CEO Harry Hixson said that the firm's lab, the Sequenom Center for Molecular Medicine, has seen samples received and billed in early 2012 increase weekly.

"We expect this trend to continue with Sequenom Center for Molecular Medicine's sustained commercial efforts throughout the year and have increased the internal goal to reflect our optimistic outlook," he said in a statement.

Sequenom's first-quarter earnings are scheduled for release after the close of the market on May 3.

In early Monday trade on the Nasdaq, shares of Sequenom were up 10 percent at $4.39.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.